← Home / Zenas BioPharma, Inc. (ZBIO)
Stock Analysis
Zenas BioPharma, Inc. (ZBIO)
ZBIO
ZBIO · Market data
19.65 +5.76%
52W Range Position
31%
LOWMIDHIGH
Trend
Mixed
Momentum
Neutral
Updated: 2026-06-18 13:43 UTC
WOI Investment Thesis
Mixed
Confirmation improves above 21.43. Holding above 19.43 keeps the current thesis intact.
⚖️
Fundamentals
Weak / Insufficient
Price Structure
Mixed
Momentum
Neutral
×
Breakout Confirmation
Pending
Risk Level
Elevated
Analysis Scope
1Y Daily
Key Decision Levels
Hold Above
Structure remains valid above support.
19.43
Break Above
Confirmation improves above resistance.
21.43
🎯
Next Objective
Pattern-derived target if setup continues.
×
Thesis Break
Scenario weakens below invalidation.
Below 19.43
What's Driving ZBIO?
📈 Technical recovery is improving
Momentum is Neutral. Watch 21.43 for confirmation and 19.43 for structure risk.
💼 Business quality remains relevant
Fundamentals remain relevant. Check growth, profitability, cash flow and balance sheet quality.
⚠️ Key risk remains
losing 19.43 would weaken the current structure.
Full Analysis Workspace
Technical Signal
Waiting for Confirmation
No confirmed breakout yet. Watch the next level and momentum behavior.
Pattern
Triangle Compression / SYM / DOWN
State
Forming
Breakout Watch
Downtrend line not broken yet · score 0
Compression
10%
RSI(14)
54.8
How to read this setup
The next meaningful technical decision is likely to occur between support at 19.43 and resistance at 21.43. Clearing resistance would strengthen the constructive case, while a failure through support would damage the present setup.
Price Chart
ZBIO · WOI overlay chart
Open Full Workspace
Business Lens
Long-term structure remains supportive
Financial quality is mixed, with cash flow or balance sheet items requiring closer monitoring.
Revenue Growth
Weak
Profitability
Insufficient
Cash Flow
Mixed
Balance Sheet
Mixed
💵 Revenue
0.00
↘ Weak
📈 Net Income
-80.99M
≈ Insufficient
🧮 EPS (Basic)
-1.46
≈ Insufficient
Zenas BioPharma, Inc.
Note: This is an algorithmic technical snapshot, not financial advice.